Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-026686
Filing Date
2025-08-14
Accepted
2025-08-14 08:15:27
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q sava20250630_10q.htm   iXBRL 10-Q 1009072
2 EXHIBIT 31.1 ex_824152.htm EX-31.1 13767
3 EXHIBIT 31.2 ex_824153.htm EX-31.2 13870
4 EXHIBIT 32.1 ex_824154.htm EX-32.1 7591
  Complete submission text file 0001437749-25-026686.txt   5235897

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sava-20250630.xsd EX-101.SCH 49430
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE sava-20250630_cal.xml EX-101.CAL 30532
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20250630_def.xml EX-101.DEF 308349
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20250630_lab.xml EX-101.LAB 275068
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20250630_pre.xml EX-101.PRE 336047
65 EXTRACTED XBRL INSTANCE DOCUMENT sava20250630_10q_htm.xml XML 845573
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41905 | Film No.: 251214504
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)